Loading
BlossomHill Therapeutics designs pills against cancer mutations and pathways that current drugs miss: BH-30643 for EGFR-mutant lung cancer that has stopped responding, BH-30236 for acute myeloid leukaemia and higher-risk myelodysplastic syndromes, and a pan-KRAS drug heading for trials in 2027.
BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), headquartered at 10255 Science Center Drive, San Diego, was incorporated in Delaware in June 2020 and develops precision small-molecule cancer medicines. BH-30643 is a non-covalent inhibitor of mutant EGFR, described in trade coverage as macrocyclic,, including the C797S and T790M resistance mutations, in the phase 1/2 SOLARA study in EGFR-mutant non-small cell lung cancer, with a companion diagnostic planned for EGFR C797S-mutated disease. BH-30236 inhibits CLK kinases, which control alternative mRNA splicing, and is in phase 1 in relapsed or refractory acute myeloid leukaemia and higher-risk myelodysplastic syndromes. BH-501284 is a preclinical pan-KRAS inhibitor that spares HRAS and NRAS, with an IND planned for the first quarter of 2027. The company listed on the Nasdaq Global Select Market in August 2026, selling 9,375,000 shares at USD 16.00; its prospectus names Cormorant Asset Management, OrbiMed, Vivo Capital and Janus Henderson Investors as holders of 5 per cent or more.
| Round | Year | Amount | Source |
|---|---|---|---|
| IPO · 9,375,000 shares at USD 16.00 per share, prospectus dated 6 August 2026; base offering before underwriting discounts and any over-allotment | 2026 | $150M | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares OrbiMed, KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
Shares Cormorant Asset Management, KRAS & RAS inhibitors, KRAS, Colorectal cancer.
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares OrbiMed, Acute myeloid leukaemia, Small-molecule kinase inhibitors.
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares KRAS & RAS inhibitors, KRAS, Small-molecule kinase inhibitors, Pancreatic ductal adenocarcinoma.
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares Cormorant Asset Management, EGFR-mutated non-small-cell lung cancer, EGFR, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/